Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma

Launched by FUJIAN MEDICAL UNIVERSITY · Jun 13, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to treat a type of thyroid cancer called papillary thyroid carcinoma that affects both sides of the thyroid gland. Instead of removing the entire thyroid, this study tests a combination of two treatments: a minimally invasive surgery to remove the main tumor on the larger side of the thyroid, and a targeted heat treatment called radiofrequency ablation (RFA) to treat a small tumor (7 mm or smaller) on the opposite side. The goal is to preserve thyroid function, reduce complications, and maintain a better quality of life compared to the usual complete thyroid removal.

Adults between 18 and 65 years old who have a tumor 1.5 cm or smaller on one side and a very small tumor (7 mm or less) on the other side may be eligible. The small tumor must be in a safe spot away from important structures, and there should be no signs of cancer spreading to lymph nodes on the other side. Participants will have both procedures done during the same anesthesia to reduce recovery time. The study will follow patients for two years to see how well the cancer is controlled, how well their thyroid function is preserved, and how safe and comfortable the treatment is. This approach could offer a less invasive option that keeps more of the thyroid working while effectively treating cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-65 years.
• • Dominant-side PTC ≤1.5 cm suitable for endoscopic resection.
• • Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule.
• • No radiologic lymph-node metastasis on contralateral side.
• • Written informed consent.
• Exclusion Criteria:
• • Extrathyroidal extension, gross nodal or distant metastasis.
• • Prior neck surgery, prior RFA/ethanol injection, or neck irradiation.
• • Pregnancy or lactation.
• • Serious comorbidities precluding anesthesia or follow-up.